$-0.36 EPS Expected for AmpliPhi Biosciences Corporation (APHB)

March 14, 2018 - By Migdalia James

 $ 0.36 EPS Expected for AmpliPhi Biosciences Corporation (APHB)

Analysts expect AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) to report $-0.36 EPS on March, 26.They anticipate $2.84 EPS change or 88.75 % from last quarter’s $-3.2 EPS. After having $-0.09 EPS previously, AmpliPhi Biosciences Corporation’s analysts see 300.00 % EPS growth. The stock increased 1.27% or $0.02 during the last trading session, reaching $1.59. About 264,988 shares traded. AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) has declined 94.86% since March 14, 2017 and is downtrending. It has underperformed by 111.56% the S&P500.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage technology. The company has market cap of $15.10 million. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. It currently has negative earnings. The firm has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults.

More notable recent AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) news were published by: Businesswire.com which released: “AmpliPhi Biosciences Provides Corporate and Strategic Update” on December 14, 2017, also Businesswire.com with their article: “AmpliPhi Biosciences Reports Fourth Quarter and Full Year 2017 Financial …” published on March 14, 2018, Marketwatch.com published: “Ampliphi Biosciences Corp.” on May 05, 2017. More interesting news about AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) were released by: Businesswire.com and their article: “AmpliPhi Biosciences to Present at Biotech Showcase 2018” published on November 28, 2017 as well as Businesswire.com‘s news article titled: “AmpliPhi Biosciences Announces Pricing of $4.0 Million Public Offering of …” with publication date: January 10, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: